Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)

Market Cap	68.97B
Revenue (ttm)	2.06B
Net Income (ttm)	-283.88M
Shares Out	222.63M
EPS (ttm)	-1.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	180,906
Average Volume	715,921
Open	314.80
Previous Close	313.20
Day's Range	307.60 - 317.20
52-Week Range	120.20 - 360.00
Beta	n/a
RSI	52.30
Earnings Date	May 19, 2025

About HKG:6990

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally. Its pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 1,837
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6990

Financial Performance

In 2024, HKG:6990's revenue was 1.93 billion, an increase of 25.48% compared to the previous year's 1.54 billion. Losses were -266.77 million, -48.92% less than in 2023.

Financial numbers in CNY